tp-0184
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 31, 2018 (NCT03429218)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- TGF-beta receptor type IINHIBITOR
TGFBR1 inhibitor
- Activin receptor type-1INHIBITOR
ACVR1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04623996 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2020 | Sumitomo Dainippon |
| NCT03429218 | Phase 1 | Mar 31, 2018 | Tolero Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sumitomo Dainippon | For profit | 1 | 1 | 1 | 2020 |
| Tolero Pharmaceuticals | For profit | 1 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1